医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

2024年06月24日 PM06:30
このエントリーをはてなブックマークに追加


 

HANGZHOU, China

HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, said today naturally occurred diabetic monkeys experienced weight loss and HbA1c level reduction during an assessment period of two months following a single injection with HFG1. The data were presented at the American Diabetes Association (ADA) 84th Scientific Sessions June 21-24, 2024, in Orlando, FL.

HFG1 is an mRNA-based GLP-1R agonist encoding a fusion protein of a GLP-1 analogue and a pH sensitive binder of human FcRn. The mRNA is loaded in proprietary lipid nanostructure particles (LNPs) designed for subcutaneous administration and local mRNA delivery. The proteins expressed are secreted and distributed into systemic circulation.

The abstract, titled “Preliminary study of efficacy and duration of an mRNA based GLP-1R agonist in diabetic monkeys,” is published on the website of the ADA’s journal Diabetes. HighField CEO and Scientific Founder Yuhong Xu, Ph.D., made the presentation of the full poster.

“We are very encouraged by the results and we are planning to file a US IND by third quarter of this year,” said Dr. Xu. “Our LNPs were developed with membrane stabilized structures. Unlike traditional LNPs for mRNA vaccination, they are more stable for storage and after injection. There was more sustained production of the transgene, enabling the GLP-1R agonist activity to be longer lasting for weeks and months. Consequently far fewer injections would be needed than existing GLP-1 products.”

The monkeys were closely monitored following HFG1 injections. The monkeys showed no serious adverse effects. They did, however, experience a reduced appetite for the first week following injection, after which their appetite returned to normal. Weight loss and A1C (HbA1c) reduction were significant.

About HighField Biopharmaceuticals

HighField is a clinical stage company focused on novel applications of liposome constructs directed to immuno-oncology and other disease treatments. The company also has a research and development center and a GMP-compliant production facility. HighField’s lead clinical development program is HFK16, a drug encapsulated immune modulating liposome. The company’s pipeline also includes an ADC platform comprised of drug encapsulated immunoliposomes for solid tumors as well as LNP therapeutics for gene delivery and gene therapy. For more information visit https://highfield.bio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624046397/en/

CONTACT

Media Contact:

Dan Eramian

Opus Biotech Communications

danieleramian@comcast.net

425-306-8716

Business Development Contact:

Donald Wyatt

HighField Biopharmaceuticals

dwyatt@hf-biopharm.com

206-356-8196

同じカテゴリーの記事 

  • Kolmar BNH Expedites European Market Expansion with its Technology-Driven HemoHIM G
  • Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
  • Fast Company Magazine Awards Xenco Medical with 2024 Innovation by Design Award for the TrabeculeX Continuum
  • PROTEINA Co., Ltd. Announces Breakthrough Research Published in Nature Biomedical Engineering
  • InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.